Study shows Daiichi's edoxaban superior to Lovenox

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said once-daily oral edoxaban for 11-14 days was superior to twice-daily Lovenox enoxaparin on the primary endpoint in the Phase III STARS J-V trial to prevent venous thromboembolism (VTE) in patients undergoing total hip replacement surgery. The oral Factor Xa inhibitor was superior to Lovenox in the incidence of symptomatic pulmonary embolism (PE) and symptomatic and asymptomatic deep vein thrombosis (DVT) (2.4% vs. 6.9%, p=0.016). All thromboembolic events were asymptomatic DVT, and there were no cases of PE or symptomatic DVT observed in either treatment group.

On the primary safety endpoint, there was no significant difference between treatment groups in the incidence of major and clinically relevant non-major bleeding (2.6% vs. 3.7%, p=0.475). The double-blind, double-dummy, Japanese trial enrolled 610 patients. Data were presented at the American Society of Hematology meeting in Orlando. ...